Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 7/20 | 0.53 |
| ▸ | MET | P08581 | 10/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | NQO2 | P16083 | 2/20 | 0.49 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE1A | P54750 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2765074 | 0.82 | KDM4E (0.59) | FYNMETPDE3BPDE3ANQO2 | |
| SCHEMBL16136542 | 0.80 | MET (0.58) | FYNMETPDE3BPDE3ANQO2 | |
| SCHEMBL18197886 | 0.79 | MET (0.59) | FYNMETPDE3BPDE3ANQO2 | |
| SCHEMBL18197857 | 0.79 | MET (0.55) | FYNMETPDE3BPDE3ANQO2 | |
| SCHEMBL2423083 | 0.78 | MET (0.57) | FYNMETPDE3BPDE3ANQO2 | |
| SCHEMBL13209254 | 0.78 | MET (0.61) | FYNMETPDE3BPDE3ANQO2 | |
| SCHEMBL4506913 | 0.74 | KDM4E (0.65) | FYNMET | |
| SCHEMBL3411895 | 0.73 | FYN (0.64) | FYNMETPDE3BPDE3ANQO2 | |
| SCHEMBL14783678 | 0.73 | FLT3 (0.52) | METPDE3BPDE3A | |
| SCHEMBL19338499 | 0.72 | FYN (0.48) | FYNMETPDE3BPDE3ANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180244695-A1 | QUINOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | SHANGHAI HAIJU BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2018-08-30 | — | — | US | disclosed |
| EP-2598144-B1 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | LILLY CO ELI (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2598144-B1 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | LILLY CO ELI (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2598144-A1 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | Eli Lilly and Company (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015677-A9 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | ELI LILLY AND COMPANY (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2012015677-A1 | 6- (1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5- | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120028984-A1 | Compound Useful As A c-MET Inhibitor | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028984-A1 | Compound Useful As A c-MET Inhibitor | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028984-A1 | Compound Useful As A c-MET Inhibitor | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244695-A1 | QUINOLINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | MET, ABL1, KRAS | FYN 1435/4885MET 1/4885PDE3B 113/4885 |
| US-10301325-B2 | Quinoline derivative, and pharmaceutical composition, preparation method and use thereof | MET, ABL1, KRAS | FYN 1435/4885MET 1/4885PDE3B 113/4885 |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | FYN 604/4885MET 1052/4885PDE3B 1674/4885 |
| US-20120028984-A1 | Compound Useful As A c-MET Inhibitor | MET, HGF, HGFAC | FYN 1510/4885MET 1/4885PDE3B 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.